Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
ProKidney (PROK) Stock Price & Analysis
113 Followers
PROK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.12 - $13.51
Previous Close$2.11
Volume279.77K
Average Volume (3M)863.52K
Market Cap
$602.24M
Enterprise Value$1.73B
Total Cash (Recent Filing)$329.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 08, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding231,698,039
10 Day Avg. Volume1,708,967
30 Day Avg. Volume863,525
Standard Deviation0.24
R-Squared0.09
Alpha-0.00892
Financial Highlights & Ratios
Price to Book (P/B)-0.53
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-13.86
Forecast
1Y Price Target
$5.00Price Target Upside136.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
ProKidney News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInterim read provides incremental confidence in REACT’s ability to stabilize eGFR in high-risk CKD patients.
Manufacturing And TrialsThe company announced resumption of manufacturing for their Phase 3 trials, with the PROACT 1 study now open for enrollment and PROACT 2 initiating sites.
Market PotentialRecent data from Novo’s semaglutide FLOW study showed limited use for patients with stage 3b-4 CKD, the market REACT is expected to be used in.
Bears Say
Clinical TrialsThe small number of patients makes it difficult to draw a definitive conclusion.
EarningsThe pivotal study delay has pushed out the approval timeline from 2026 to 2027.
Market PerformanceToday's weakness (PROK down ~9% vs XBI ~1%) is attributed to exiting of positions after playing the catalyst and concerns around competitive GLP-1 usage.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $1.12 and its highest was $13.51 in the past 12 months.
What is ProKidney’s market cap?
Currently, no data Available
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on May 10, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.293 by $0.133.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -$0.28.
How many shares outstanding does ProKidney have?
ProKidney has 117,698,020 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.293. Following the earnings report the stock price went up 7.663%.
Which hedge fund is a major shareholder of ProKidney?
Among the largest hedge funds holding ProKidney’s share is Wexford Capital LP. It holds ProKidney’s shares valued at N/A.
---
ProKidney Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (136.97% Upside)
$5.00 (136.97% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 12.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $75.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.2%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-81.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.69%
Trailing 12-Months
Company Description
ProKidney
Social Capital Suvretta Holdings Corp III is a blank check company.
---
PROK Company Deck
---
PROK Earnings Call
Q3 2023
0:00 / 0:00
---
PROK Stock 12 Month Forecast
Average Price Target
$5.00
▲(136.97% Upside)
Technical Analysis
Best Analysts Covering PROK
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-28.13%
reiterated a buy rating last month
Copying Justin Zelin's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -28.13% per trade.
---